Nimolicinol
Nimolicinol is a tetranortriterpenoid compound. Nimolicinol binds to the ephrinB2 interaction interface of the Nipah virus attachment glycoprotein, interfering with virus-host cell adhesion, and exhibits anti-Plasmodium, anti-SARS-CoV-2, and larvicidal activities. Nimolicinol can be used in research on Nipah virus infection, malaria, COVID-19, and filariasis.
For research use only. We do not sell to patients.
- CAS No.: 89366-02-9
- Formula: C28H34O7
- Molecular Weight:482.57
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Parasite Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HL-60 | IC50 |
> 20 μM
Compound: 19
|
Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 21381696] |
| SK-BR-3 | IC50 |
> 20 μM
Compound: 19
|
Cytotoxicity against human SK-BR-3 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human SK-BR-3 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 21381696] |
| A549 | IC50 |
> 20 μM
Compound: 19
|
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 21381696] |
| AZ-521 cell line | IC50 |
> 20 μM
Compound: 19
|
Cytotoxicity against human AZ-521 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human AZ-521 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 21381696] |
In Vitro
Nimolicinol (NCL) binds the Nipah virus attachment glycoprotein with a docking ΔG of -9.265 kcal/mol (RMSD 1.957 Å), interacting with Leu124, Asp219, Phe458, Val507, and Lys560 through hydrophobic contacts, with Tyr508 and Gln559 through hydrogen bonds, and with Arg236 through a salt bridge, all within Cavity I[1].
Nimolicinol (compound 4) is a known tetranortriterpenoid isolated from Azadirachta indica neem seed oil[2].
Nimolicinol binds to pfpk5 through hydrogen bonding and pi interactions, with a binding energy of -5.5 kcal/mol, exhibiting the highest binding affinity among the tested limonoids and supporting its potential as a pfpk5 inhibitor[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Nimolicinol (10-50 ppm; aqueous larval medium) exhibited weak larvicidal activity against Culex quinquefasciatus, causing 30% mortality at 50 ppm and 15% mortality at 10 ppm after 48 h[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Aedes aegypti (fourth instar larvae)[5]
-
Dosage:50 ppm; 10 ppm
-
Administration:aqueous larval medium
-
Result:Produced 20% mortality at 48 h at 10 and 50 ppm.
-
Animal Model:Culex quinquefasciatus (fourth instar larvae)[5]
-
Dosage:50 ppm; 10 ppm
-
Administration:aqueous larval medium
-
Result:Produced 30% mortality at 48 h at 10 and 50 ppm.
Chemical Information
-
CAS No. 89366-02-9
-
Molecular Weight 482.57
-
Formula C28H34O7
-
SMILES
C[C@]12C([C@]([C@](O3)(C4=COC=C4)O)(CC[C@]1([H])[C@@]5([C@@](C(C)(C(C=C5)=O)C)([H])C[C@H]2OC(C)=O)C)C)=CC3=O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)